HIV

The Ragon’s first research priority area was HIV, a devastating epidemic affecting millions of people worldwide. Our goal is to eradicate HIV by working collaboratively with scientists and affected communities in South Africa, the epicenter of the HIV epidemic.

At the Ragon, engineers, immunologists, clinicians, computational biologists, and immunogeneticists work together to integrate key facets of current vaccine development efforts across separate tracks to drive efforts for an efficacious vaccine.

We have one promising vaccine candidate in a clinical efficacy trial in Africa and several additional HIV vaccine concepts in development.

In addition, our labs have uncovered the mechanisms behind the ability of elite controllers to control HIV without the need for medication. These unique individuals have immune systems that can contain the virus and understanding their immune systems can help lead to a curative treatment for HIV.

Labs Working in this Area

On Site Labs

Allen

T Cell Immunotherapy, HIV Evolution and Transmission

Todd Allen, PhD

LAB INFO

Balazs

Engineering Immunity Against Infectious Disease

Alejandro B. Balazs, PhD

LAB INFO

Batista

B cells, antibodies, preclinical vaccinology

Facundo Batista, PhD

LAB INFO

Gaiha

T cells, Vaccines, & Immune Control

Gaurav D. Gaiha, MD, DPhil

LAB INFO

Juelg

Natural infections informing immunotherapies

Boris D. Juelg, MD, PhD

LAB INFO

Kwon

Mucosal immunology, Microbiome, HIV

Douglas S. Kwon, MD, PhD

LAB INFO

Lingwood

Programing vaccine antibody responses

Daniel Lingwood, PhD

LAB INFO

Ndung’u

Immune mechanisms of HIV control

Thumbi Ndung’u, PhD

LAB INFO

Shalek

Single-Cell Genomics, Systems Immunology

Alex K. Shalek, PhD

LAB INFO

Walker

HIV, virus-specific T cells, elite controllers

Bruce D. Walker, MD

LAB INFO